Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | April 25, 2014 | April 29, 2014 |
| Amesite Inc.NONE · Entity 149985 | Director | March 31, 2020 | April 06, 2020 |
| Amesite Inc.AMST · Entity 8151 | Director | September 30, 2026 | October 03, 2026 |
| Elicio Therapeutics, Inc.ANGN · Entity 299 | Director | June 09, 2022 | June 13, 2022 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | April 17, 2017 | April 19, 2017 |
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 25, 2014 · Filed April 29, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,547 |
Reported balance
After 2014-04-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2014-04-25 · Grant · Acquired 1,795 · Balance 180,547 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
F2: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
Amesite Inc.
Report date March 31, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-03-31 | Direct | 50,000 |
Reported balance
After 2020-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-31 · Grant · Acquired 50,000 · Balance 50,000 F1: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-03-31 | Direct | 10,000 |
Reported balance
After 2020-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-31 · Grant · Acquired 10,000 · Balance 10,000 F2: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter.
F2: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter.
Amesite Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Gilbert S. Omenn Revocable Trust | 95,927 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 12,121 · Balance 95,927 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AMST common stock and/or the cash equivalent of such share. F2: The reported securities were issued as "deferred stock units" in lieu of cash compensation earned for services as a director, and the number of deferred stock units received was calculated based on the closing share price on the last day of the quarter. The deferred stock units or cash equivalent will be issued to the reporting person upon completion of service as a member of the board of directors or, if earlier, a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AMST common stock and/or the cash equivalent of such share.
F2: The reported securities were issued as "deferred stock units" in lieu of cash compensation earned for services as a director, and the number of deferred stock units received was calculated based on the closing share price on the last day of the quarter. The deferred stock units or cash equivalent will be issued to the reporting person upon completion of service as a member of the board of directors or, if earlier, a change in control.
Elicio Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2032-06-09 | Direct | 15,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Esperion Therapeutics, Inc.
Report date April 17, 2017 · Filed April 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2027-04-17 | Direct | 14,000 |
Reported balance
After 2017-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-17 · Grant · Acquired 14,000 · Balance 14,000 F1: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017.
GALECTIN THERAPEUTICS INC
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-01-16 | Direct | 60,000 |
Reported balance
After 2026-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest 100% on December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 200 | $58.08 | $11,616.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 13 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,340 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 4,700 | $58.00 | $272,600.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 12 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,540 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $57.88 | $5,788.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 11 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,240 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 600 | $58.04 | $34,824.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 10 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,340 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 400 | $58.14 | $23,256.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 9 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,940 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $58.25 | $17,475.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 8 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,340 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $58.24 | $17,472.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 7 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,640 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 400 | $58.21 | $23,284.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 6 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,940 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 6,200 | $58.20 | $360,840.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 5 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,340 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $58.39 | $5,839.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,540 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $58.38 | $5,838.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,640 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $58.36 | $5,836.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,740 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 16,000 | $28.97 | $463,500.80 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2008 Filed May 1, 2008 21:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $42.13 Strike: $42.13 | $210,650.00 |
DisclosureSEC source: 0001181431-08-028025 · rrd204681.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2015-04-29 Read SEC document |
| April 29, 2008 Filed May 1, 2008 21:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-08-028025 · rrd204681.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,840 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director hah had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| January 25, 2008 Filed Jan 28, 2008 22:56 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO ( Right to Buy) · Derivative | 1,000 | $45.45 Strike: $45.45 | $45,450.00 |
DisclosureSEC source: 0001181431-08-005841 · rrd192252.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,323 Underlying: Common Stock · 1,000 shares Expires 2008-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2008 Filed Jan 28, 2008 22:56 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 1,000 | $45.45 | $45,450.00 |
DisclosureSEC source: 0001181431-08-005841 · rrd192252.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2008 Filed Jan 24, 2008 17:36 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 4,323 | $45.45 Strike: $45.45 | $196,480.35 |
DisclosureSEC source: 0001181431-08-005076 · rrd191582.xml · derivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,323 Underlying: Common Stock · 4,323 shares Expires 2008-01-27 Read SEC document |
| January 23, 2008 Filed Jan 24, 2008 17:36 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 16,000 | $12.28 Strike: $12.28 | $196,500.80 |
DisclosureSEC source: 0001181431-08-005076 · rrd191582.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 16,000 shares Expires 2008-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2008 Filed Jan 24, 2008 17:36 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,323 | $45.45 | $196,480.35 |
DisclosureSEC source: 0001181431-08-005076 · rrd191582.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,467 Read SEC document |
| January 23, 2008 Filed Jan 24, 2008 17:36 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 16,000 | $12.28 | $196,500.80 |
DisclosureSEC source: 0001181431-08-005076 · rrd191582.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2007 Filed Apr 30, 2007 17:37 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $62.55 Strike: $62.55 | $312,750.00 |
DisclosureSEC source: 0001181431-07-027938 · rrd155969.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2014-04-26 Read SEC document |
| April 26, 2007 Filed Apr 30, 2007 17:37 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-07-027938 · rrd155969.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,790 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| January 25, 2007 Filed Jan 25, 2007 23:22 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 11,600 | $13.73 Strike: $13.73 | $159,319.04 |
DisclosureSEC source: 0001181431-07-005858 · rrd144269.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,600 shares Expires 2007-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2007 Filed Jan 25, 2007 23:22 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,120 | $75.14 | $159,296.80 |
DisclosureSEC source: 0001181431-07-005858 · rrd144269.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,192 Read SEC document |
| January 25, 2007 Filed Jan 25, 2007 23:22 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 11,600 | $13.73 | $159,319.04 |
DisclosureSEC source: 0001181431-07-005858 · rrd144269.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,312 Read SEC document |
| December 15, 2006 Filed Dec 19, 2006 01:15 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-06-070580 · rrd139743.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,712 Read SEC document |
| March 15, 2006 Filed Mar 17, 2006 18:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $74.89 | $0.00 |
DisclosureSEC source: 0001181431-06-018682 · rrd111489.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2013-03-15 Read SEC document |
| March 15, 2006 Filed Mar 17, 2006 18:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-06-018682 · rrd111489.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,392 F1 · balance_after: Includes shares equivalent to Restricted Stock Units, which were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan, which were paid in shares of the Company's common stock on a one-to-one basis shortly after vesting, and which were previously identified as Restricted Stock Units on Table 1. Read SEC document |
| March 03, 2006 Filed Mar 7, 2006 18:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 600 | $76.85 | $46,110.00 |
DisclosureSEC source: 0001181431-06-016614 · rrd110340.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,057 F1 · balance_after: Amount of securities beneficially owned has been adjusted to reflected Amgen Inc.'s obligations under the Contractual Contingent Payment Right arising from the the purchase by Amgen Inc, from the reporting person of Two Class A intrests of Amgen Clinical Partners, L.P. terminated on December 31, 2005, with the final quarterly payment be made on February 28, 2006. Read SEC document |
| March 03, 2006 Filed Mar 7, 2006 18:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $76.74 | $76,740.00 |
DisclosureSEC source: 0001181431-06-016614 · rrd110340.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,657 F1 · balance_after: Amount of securities beneficially owned has been adjusted to reflected Amgen Inc.'s obligations under the Contractual Contingent Payment Right arising from the the purchase by Amgen Inc, from the reporting person of Two Class A intrests of Amgen Clinical Partners, L.P. terminated on December 31, 2005, with the final quarterly payment be made on February 28, 2006. Read SEC document |
| March 01, 2006 Filed Mar 3, 2006 22:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 400 | $76.24 | $30,496.00 |
DisclosureSEC source: 0001181431-06-016235 · rrd109978.xml · nonDerivative · entry 5 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,657 Read SEC document |
| March 01, 2006 Filed Mar 3, 2006 22:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 600 | $76.22 | $45,732.00 |
DisclosureSEC source: 0001181431-06-016235 · rrd109978.xml · nonDerivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,057 Read SEC document |
| March 01, 2006 Filed Mar 3, 2006 22:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 700 | $76.16 | $53,312.00 |
DisclosureSEC source: 0001181431-06-016235 · rrd109978.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,657 Read SEC document |
| March 01, 2006 Filed Mar 3, 2006 22:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $76.11 | $22,833.00 |
DisclosureSEC source: 0001181431-06-016235 · rrd109978.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,357 Read SEC document |
| March 01, 2006 Filed Mar 3, 2006 22:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCCPR | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-06-016235 · rrd109978.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0.5 F1 · date: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · deemedExecutionDate: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · kind: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · shares: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · price: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · acquired: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · balance_after: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. F1 · ownership.direct: (GO-CCPR)Contractual Contingent payment rights arising from the purchase by Amgen Inc, of two class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| February 22, 2006 Filed Feb 23, 2006 18:28 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,000 | $75.26 | $150,520.00 |
DisclosureSEC source: 0001181431-06-013735 · rrd109104.xml · nonDerivative · entry 7 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,657 Read SEC document |
| February 22, 2006 Filed Feb 23, 2006 18:28 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $75.25 | $75,250.00 |
DisclosureSEC source: 0001181431-06-013735 · rrd109104.xml · nonDerivative · entry 6 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,657 Read SEC document |
| February 22, 2006 Filed Feb 23, 2006 18:28 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $75.03 | $22,509.00 |
DisclosureSEC source: 0001181431-06-013735 · rrd109104.xml · nonDerivative · entry 5 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,657 Read SEC document |
| February 22, 2006 Filed Feb 23, 2006 18:28 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $75.02 | $22,506.00 |
DisclosureSEC source: 0001181431-06-013735 · rrd109104.xml · nonDerivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,957 Read SEC document |
| February 22, 2006 Filed Feb 23, 2006 18:28 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 400 | $75.01 | $30,004.00 |
DisclosureSEC source: 0001181431-06-013735 · rrd109104.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,257 Read SEC document |
| February 22, 2006 Filed Feb 23, 2006 18:28 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,000 | $74.99 | $149,980.00 |
DisclosureSEC source: 0001181431-06-013735 · rrd109104.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,657 Read SEC document |
| January 25, 2006 Filed Jan 27, 2006 23:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 9,600 | $14.72 Strike: $14.72 | $141,300.48 |
DisclosureSEC source: 0001181431-06-006204 · rrd104941.xml · derivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,600 shares Expires 2006-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2006 Filed Jan 27, 2006 23:45 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,885 | $74.94 | $141,261.71 |
DisclosureSEC source: 0001181431-06-006204 · rrd104941.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,657 F2 · balance_after: The reporting person no longer has a reportable beneficial interest in 5,590 shares of Amgen Inc. common stock owned by his son and included in the reporting person's prior ownership reports. Read SEC document |
| January 25, 2006 Filed Jan 27, 2006 23:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 9,600 | $14.72 | $141,300.48 |
DisclosureSEC source: 0001181431-06-006204 · rrd104941.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The reporting person no longer has a reportable beneficial interest in 5,590 shares of Amgen Inc. common stock owned by his son and included in the reporting person's prior ownership reports. Read SEC document |
| December 08, 2005 Filed Dec 12, 2005 17:33 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-05-066000 · rrd99620.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,942 Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 01:18 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.61 | $0.00 |
DisclosureSEC source: 0001181431-05-017375 · rrd72860.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2015-03-15 Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 01:18 UTC | AMGEN INC AMGN · Entity 2832 | GrantRestricted Stock Units | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-05-017375 · rrd72860.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,706 F1 · security: (DIR 03.15.05) The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. F2 · balance_after: (GSO 3.15.05) Does not include (i) 5,590 shares held as indirect ownership by reporting person's son and (ii) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| March 07, 2005 Filed Mar 8, 2005 18:17 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 500 | $62.59 | $31,295.00 |
DisclosureSEC source: 0001181431-05-015245 · rrd71678.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| March 07, 2005 Filed Mar 8, 2005 18:17 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 500 | $62.52 | $31,260.00 |
DisclosureSEC source: 0001181431-05-015245 · rrd71678.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,511 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.